MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint

Benjamin A H Smith1,2, Anja Deutzmann3, Kristina M Correa4

  • 1Sarafan ChEM-H, Stanford University, Stanford, CA 94305.

Insights

The MYC oncogene drives cancer immune evasion by controlling the production of disialyl-T, a "don't eat me" signal that engages Siglec receptors on immune cells. This discovery offers new targets for cancer immunotherapy.

Area of Science:

  • Immunology
  • Glycobiology
  • Oncology

Background:

  • Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that inhibit immune cell activation.
  • The mechanisms controlling Siglec ligand production on cancer cells, crucial for tumor immune evasion, are not well understood.

Purpose of the Study:

  • To investigate the role of the MYC oncogene in regulating Siglec ligand production and its impact on tumor immune evasion.
  • To identify the specific glycan ligand and its associated enzymes involved in MYC-driven immune suppression.

Main Methods:

  • Glycomics and RNA-sequencing of mouse tumors to analyze gene expression and glycan profiles.
  • In vivo mouse models and analysis of primary human leukemias to validate findings.
  • Functional assays to assess the interaction between disialyl-T and Siglec receptors.

Main Results:

  • The MYC oncogene was found to causally regulate the expression of the sialyltransferase ST6GALNAC4, leading to the production of the disialyl-T glycan.
  • Disialyl-T acts as a "don't eat me" signal by binding to macrophage Siglec-E (mouse) or Siglec-7 (human), inhibiting cancer cell clearance.
  • High MYC and ST6GALNAC4 expression correlates with high-risk cancers and reduced myeloid cell infiltration in tumors.

Conclusions:

  • MYC oncogene regulates cancer cell glycosylation to promote immune evasion by inducing disialyl-T.
  • Disialyl-T functions as a glycoimmune checkpoint ligand, making it a potential target for antibody-based therapies.
  • ST6GALNAC4, the enzyme synthesizing disialyl-T, is a potential target for small molecule-based immunotherapies.

Related Concept Videos

Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Oligosaccharide Assembly01:24

Oligosaccharide Assembly

Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
2.9K
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.4K
Cell-surface Signaling01:21

Cell-surface Signaling

Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
52.0K